BENIGN OVARIAN LESION VS OVARIAN CANCER ENDOMETRIOID CYST VS OVARIAN CANCER  DERMOID CYST VS OVARIAN CANCER  BENIGN EPITHELIAL TUMOR VS OVARIAN CANCER  OTHER BENIGN LESION VS  OVARIAN CANCER
All PM M All PM M All PM M All PM M All PM M
SENSITIVITY [%] ROMA 88 76.2 91.9 88 78.3 - 88 78.3 - 88 78.3 91.9 88 78.3 -
ROMA1 85.5 76.2 88.7 85.5 78.3 - 85.5 78.3 - 85.5 78.3 88.7 85.5 78.3 -
HE4 79.5 71.4 81.7 79.5 73.9 - 79.5 73.9 - 79.5 73.9 81.7 79.5 73.9 -
CA125 90.4 85.7 91.7 90.4 85.7 - 90.4 85.7 - 90.4 85.7 91.7 90.4 86.7 -
SPECIFICITY [%] ROMA 88.5 91.6 80.6 83.3 85.7 - 95 94.1 - 85.3 100 72.7 91.2 89.5 -
ROMA1 95.4 96.8 91.7 96.3 95.8 - 100 100 - 91.9 100 86.4 93.4 92.3 -
HE4 87.8 89.5 83.3 92.6 90.9 - 95 94.1 - 81.1 100 90.9 89.5 87.2 -
CA125 72.5 71.6 75 45.8 54.2 - 90 88.2 - 70.6 85.7 59.9 79.2 71.7 -
PPV [%] ROMA 83 66.7 88.7 94.8 85.7 - 98.6 94.7 - 93.4 100 90.2 94.8 83.3 -
ROMA1 92.2 84.2 87.5 98.6 94.7 - 100 100 - 95.9 100 94.6 95.9 85.7 -
HE4 80.4 60 89.1 97.1 89.5 - 98.5 94.4 - 90.4 100 96.1 92.9 77.3 -
CA125 67.6 40 85.9 85.2 61.9 - 97.4 90.9 - 88.2 90.9 85.9 88.2 64.5 -
NPV [%] ROMA 92.1 94.6 85.3 66.6 78.3 - 65.5 76.2 - 74.4 66.6 76.2 81.5 82.9 -
ROMA1 91.2 94.8 82.5 74.3 82.1 - 76.5 77.3 - 85 75 73.1 83.3 87.8 -
HE4 87.1 93.4 73.2 59.5 78.6 - 52.7 72.7 - 63.8 71.4 64.5 71.7 85 -
CA125 92.2 95.8 84.4 57.9 78.5 - 69.2 83.3 - 75 80 72.2 82.6 90.3 -
All – PM+M; PM – Premenopause; M – Postmenopause ; ROMA 1 – risk stratification based on cutoff points determined by authors
Table 3: Sensitivity, specificity, PPV, and NPV of CA125, HE4, and ROMA for ovarian cancer screening in patients with a pelvic mass.